PDF(Pubmed)
Abstract：
UNASSIGNED: In December 2020, Canada began its coronavirus disease 2019 (COVID-19) vaccine rollout campaign. Canadians were vaccinated with differing time intervals between doses, vaccine products and vaccine schedules, based on age, timing of vaccination and jurisdiction. The objective of this study is to describe the epidemiology and association between the incidence of COVID-19 cases following vaccination, time since completion of primary series, time between doses and/or product combination and probability of developing severe outcomes.
UNASSIGNED: The national COVID-19 case data and vaccination coverage data were extracted from the National COVID-19 Surveillance System, and the Canadian COVID-19 Vaccination Coverage Surveillance System. Population estimates from Statistics Canada were used as denominators for rates and for number of people \"not fully vaccinated\". Two binomial generalized linear models were constructed for analysis.
UNASSIGNED: Within the analysis period, fully vaccinated (i.e. completed primary series) cases (n=17,206) were more commonly female and older, and had fewer reported severe outcomes relative to not fully vaccinated cases (n=615,999). Episode date of fully vaccinated cases most frequently occurred two months after receiving their second dose, and time-between doses of 29-49 and 50-77 days were most common. The probability of becoming a detected COVID-19 case in not fully vaccinated individuals was higher than those fully vaccinated. Those receiving two doses of AstraZeneca and those with shortest time intervals between doses had higher probabilities of becoming COVID-19 cases.
UNASSIGNED: Findings from Canada\'s national surveillance systems support that being fully vaccinated against COVID-19, having a longer time interval between doses and receiving a messenger ribonucleic acid (mRNA) COVID-19 vaccine schedule compared to other vaccines reduce the probability of becoming a case, using data from January to August 2021.
UNASSIGNED: The national COVID-19 case data and vaccination coverage data were extracted from the National COVID-19 Surveillance System, and the Canadian COVID-19 Vaccination Coverage Surveillance System. Population estimates from Statistics Canada were used as denominators for rates and for number of people \"not fully vaccinated\". Two binomial generalized linear models were constructed for analysis.
UNASSIGNED: Within the analysis period, fully vaccinated (i.e. completed primary series) cases (n=17,206) were more commonly female and older, and had fewer reported severe outcomes relative to not fully vaccinated cases (n=615,999). Episode date of fully vaccinated cases most frequently occurred two months after receiving their second dose, and time-between doses of 29-49 and 50-77 days were most common. The probability of becoming a detected COVID-19 case in not fully vaccinated individuals was higher than those fully vaccinated. Those receiving two doses of AstraZeneca and those with shortest time intervals between doses had higher probabilities of becoming COVID-19 cases.
UNASSIGNED: Findings from Canada\'s national surveillance systems support that being fully vaccinated against COVID-19, having a longer time interval between doses and receiving a messenger ribonucleic acid (mRNA) COVID-19 vaccine schedule compared to other vaccines reduce the probability of becoming a case, using data from January to August 2021.
摘要：
■2020年12月，加拿大开始了2019年冠状病毒病（COVID-19）疫苗推广活动。加拿大人接种疫苗的时间间隔不同,疫苗产品和疫苗时间表，根据年龄,疫苗接种时间和管辖权。这项研究的目的是描述疫苗接种后COVID-19病例的流行病学和发病率之间的关系，自完成主要系列以来的时间，剂量和/或产品组合之间的时间以及发生严重结局的可能性。
■国家COVID-19病例数据和疫苗接种覆盖率数据是从国家COVID-19监测系统中提取的，和加拿大COVID-19疫苗接种覆盖率监测系统。加拿大统计局的人口估计被用作“未完全接种疫苗”的比率和人数的分母。构建了两个二项广义线性模型进行分析。
■在分析期内，完全接种疫苗（即完成的主要系列）病例（n=17,206）更常见的是女性和老年人，与未完全接种疫苗的病例相比,报告的严重结局较少(n=615,999).完全接种疫苗病例的发病日期最常见的是在接受第二剂疫苗后两个月，29-49天至50-77天的剂量间隔时间是最常见的。在未完全接种疫苗的个体中，成为检测到的COVID-19病例的可能性高于完全接种疫苗的个体。那些接受两剂阿斯利康和剂量间隔最短的人成为COVID-19病例的可能性更高。
■来自加拿大国家监测系统的结果支持，与其他疫苗相比，完全接种COVID-19疫苗，剂量之间的时间间隔更长，接受信使核糖核酸（mRNA）COVID-19疫苗的时间表降低了成为病例的可能性，使用2021年1月至8月的数据。
■国家COVID-19病例数据和疫苗接种覆盖率数据是从国家COVID-19监测系统中提取的，和加拿大COVID-19疫苗接种覆盖率监测系统。加拿大统计局的人口估计被用作“未完全接种疫苗”的比率和人数的分母。构建了两个二项广义线性模型进行分析。
■在分析期内，完全接种疫苗（即完成的主要系列）病例（n=17,206）更常见的是女性和老年人，与未完全接种疫苗的病例相比,报告的严重结局较少(n=615,999).完全接种疫苗病例的发病日期最常见的是在接受第二剂疫苗后两个月，29-49天至50-77天的剂量间隔时间是最常见的。在未完全接种疫苗的个体中，成为检测到的COVID-19病例的可能性高于完全接种疫苗的个体。那些接受两剂阿斯利康和剂量间隔最短的人成为COVID-19病例的可能性更高。
■来自加拿大国家监测系统的结果支持，与其他疫苗相比，完全接种COVID-19疫苗，剂量之间的时间间隔更长，接受信使核糖核酸（mRNA）COVID-19疫苗的时间表降低了成为病例的可能性，使用2021年1月至8月的数据。
